TAVEXIA : BOARD APPROVES FUND RAISE OF UP TO RS 68 CR FOR 60% STAKE IN MEYONEX PHARMA

• Board gave in-principle approval to raise up to ₹68 Cr through preferential issue, rights issue or any other permissible mode, in one or more tranches • Proceeds to finance the proposed acquisition of 60% of the equity share capital of Meyonex Pharmaceuticals Limited, approved by the board on 7 October 2026 • Final decision on mode, structure, terms and conditions of the fund raise to be taken at a subsequent board meeting • Q2 trading business revenue fell to ₹0.16 Cr from ₹1.96 Cr (YOY); H1 revenue at ₹0.39 Cr v ₹3.18 Cr • Board approved change in Registrar and Transfer Agent from Niche Technologies to Skyline Financial Services

Tavexia Lifecare Ltd

Open attachment

← Back to feed